气道组胺H_2受体与支气管哮喘发病机理关系的临床研究

The relationship between H_2 receptor of air ways andthe pathogenesis of bronchial asthma.

应用组胺Ｈ＿２受体（Ｈ＿２Ｒ）激动剂甲双咪胍治疗缓解期哮喘患者１９例，观察其对气道高反应性（ＢＨＲ）的作用，以进一步探讨Ｈ＿２Ｒ与哮喘发病机理的关系。结果表明：甲双咪胍２．５ｍｇ１次吸入对哮喘患者（１３例）起始呼吸阻力（Ｒｒｓ）和乙酰甲胆碱累积剂量反应阈值（Ｄｍｉｎ）均无显著作用；而用２．５ｍｇ每日１次连续吸入１０日后（６例）Ｒｒｓ较治疗前有所降低（Ｐ＝０．０５９），Ｄｍｉｎ显著升高（Ｐ＜０．０５），表明甲双咪胍虽可降低气道平滑肌基础张力，但尚无统计学意义，而能明显降低气道对乙酰甲胆碱的敏感性，即改善ＢＨＲ。研究提示Ｈ＿２Ｒ激动剂可主要作为抗气道炎症用药，也可作为平喘药的辅助用药；说明Ｈ＿２Ｒ在哮喘气道炎症反应中具有保护作用。

n order to explore thefblat ionshi pbetween H_2Rand the pathogenesis of asthma,we treated 19 stableasthmatic patients with H_2-receptor against impromidineand observed its effect on bronchial hyperresponsiveness(BHR ). The results showed that single dose inhalationof impromidine(2.5mg,in 13 cases ) had no effect onthe starting respiratory resistance(Rrs)and the mini-mum amount of cumulative dose( Dmin)to asthmaticairways,while repetitive inhalation of impromidine for10 days(2. 5mg a day, in 6 cases)decreased the Rrs(P=0.05 9)and increased the Dmin significantly(P<0. 05);and that H_2R against impromidine could reducethe sensitivity of airway to methacholine and improvethe BHR of asthmatic patients. The results suggest thatH_2R against may be used as anti-inflammatory drug totreat asthma and H_2R may have protective role in theinflammatory reaction of asthmatic airways.